Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- CirQuest Labs, LLC
- Registration Number
- NCT03027934
Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study
- Conditions
- Acute Coronary SyndromeSTEMI
- Interventions
- First Posted Date
- 2017-01-10
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT03016611
- Locations
- 🇮🇱
Sheba Medical center, Ramat Gan, Israel
Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.
- Conditions
- STEMI - ST Elevation Myocardial InfarctionCoronary Artery Disease
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2020-02-21
- Lead Sponsor
- Insel Gruppe AG, University Hospital Bern
- Target Recruit Count
- 122
- Registration Number
- NCT02978040
- Locations
- 🇨🇭
Bern University Hospital, Bern, Switzerland
🇮🇹University of Ferrara, Ferrara, Italy
🇮🇹University of Naples Federico II, Naples, Italy
Half Dose of Prasugrel and Ticagrelor in Acute Coronary Syndrome (HOPE-TAILOR)
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Dong-A University
- Target Recruit Count
- 120
- Registration Number
- NCT02944123
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-05-06
- Lead Sponsor
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
- Target Recruit Count
- 1506
- Registration Number
- NCT02866175
- Locations
- 🇺🇦
Kharkiv City Clinical Hospital #8, Kharkiv, Ukraine
🇬🇧Altnagelvin Area Hospital, Londonderry, United Kingdom
🇬🇧Golden Jubilee Hospital, Clydebank, United Kingdom
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
- Conditions
- Myocardial InfarctionAngioplasty, Balloon, CoronaryPlatelet Aggregation Inhibitors
- Interventions
- First Posted Date
- 2016-06-22
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- Faculty Hospital Kralovske Vinohrady
- Target Recruit Count
- 1226
- Registration Number
- NCT02808767
- Locations
- 🇨🇿
Faculty Hospital Kralovske Vinohrady, Prague, Czechia
Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function in Humans (HI-TECH)
- Conditions
- Cardiovascular Diseases
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT02587260
- Locations
- 🇨🇭
Inselspitäl University Medical Center, Bern, Switzerland
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇮🇹Policlinico San Matteo, Pavia, Italy
Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention
- First Posted Date
- 2015-09-14
- Last Posted Date
- 2020-07-17
- Lead Sponsor
- LMU Klinikum
- Target Recruit Count
- 795
- Registration Number
- NCT02548611
- Locations
- 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
🇩🇪Munich University Hospital, Munich, Bavaria, Germany
🇩🇪Klinikum Bogenhausen, Munich, Germany
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2015-09-10
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 130
- Registration Number
- NCT02545933
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Ticagrelor vs. Prasugrel Effects on Infarct Size
- Conditions
- Cardiovascular Disease
- Interventions
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Yochai Birnbaum
- Registration Number
- NCT02507323
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Memorial Hermann Hospital, Houston, Texas, United States
🇺🇸Baylor-St. Lukes Medical Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.